UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to promote the lymphatic metastasis of bladder cancer.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
08 07 2023
Historique:
received: 18 01 2023
accepted: 30 06 2023
medline: 10 7 2023
pubmed: 9 7 2023
entrez: 8 7 2023
Statut: epublish

Résumé

Lymphatic metastasis is the most common pattern of bladder cancer (BCa) metastasis and has an extremely poor prognosis. Emerging evidence shows that ubiquitination plays crucial roles in various processes of tumors, including tumorigenesis and progression. However, the molecular mechanisms underlying the roles of ubiquitination in the lymphatic metastasis of BCa are largely unknown. In the present study, through bioinformatics analysis and validation in tissue samples, we found that the ubiquitin-conjugating E2 enzyme UBE2S was positively correlated with the lymphatic metastasis status, high tumor stage, histological grade, and poor prognosis of BCa patients. Functional assays showed that UBE2S promoted BCa cell migration and invasion in vitro, as well as lymphatic metastasis in vivo. Mechanistically, UBE2S interacted with tripartite motif containing 21 (TRIM21) and jointly induced the ubiquitination of lipoma preferred partner (LPP) via K11-linked polyubiquitination but not K48- or K63-linked polyubiquitination. Moreover, LPP silencing rescued the anti-metastatic phenotypes and inhibited the epithelial-mesenchymal transition of BCa cells after UBE2S knockdown. Finally, targeting UBE2S with cephalomannine distinctly inhibited the progression of BCa in cell lines and human BCa-derived organoids in vitro, as well as in a lymphatic metastasis model in vivo, without significant toxicity. In conclusion, our study reveals that UBE2S, by interacting with TRIM21, degrades LPP through K11-linked ubiquitination to promote the lymphatic metastasis of BCa, suggesting that UBE2S represents a potent and promising therapeutic target for metastatic BCa.

Identifiants

pubmed: 37422473
doi: 10.1038/s41419-023-05938-2
pii: 10.1038/s41419-023-05938-2
pmc: PMC10329682
doi:

Substances chimiques

SS-A antigen 0
Transcription Factors 0
Ube2S protein, human EC 2.3.2.23
Ubiquitin-Conjugating Enzymes EC 2.3.2.23
Ribonucleoproteins 0
LPP protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

408

Informations de copyright

© 2023. The Author(s).

Références

Clin Cancer Res. 2019 Feb 15;25(4):1389-1403
pubmed: 30397178
Immunity. 2016 Jul 19;45(1):15-30
pubmed: 27438764
Eur Urol. 2012 May;61(5):1039-47
pubmed: 22381169
Signal Transduct Target Ther. 2021 Dec 20;6(1):422
pubmed: 34924561
Mol Cancer. 2022 Nov 14;21(1):210
pubmed: 36376892
Signal Transduct Target Ther. 2020 Feb 29;5(1):11
pubmed: 32296023
Cell Death Dis. 2021 Jan 22;12(1):118
pubmed: 33483464
Nucleic Acids Res. 2022 Feb 22;50(3):1517-1530
pubmed: 35048968
J Exp Clin Cancer Res. 2021 Jun 21;40(1):203
pubmed: 34154613
Elife. 2022 Aug 05;11:
pubmed: 35929733
Cancer Sci. 2019 Sep;110(9):2822-2833
pubmed: 31278883
J Adv Res. 2022 Jul;39:187-202
pubmed: 35777908
Signal Transduct Target Ther. 2021 Feb 16;6(1):64
pubmed: 33589597
Int J Biol Sci. 2022 May 16;18(8):3528-3543
pubmed: 35637955
J Autoimmun. 2012 Aug;39(1-2):77-82
pubmed: 22402340
Theranostics. 2021 Mar 4;11(10):4809-4824
pubmed: 33754029
Oncogene. 2016 Feb 25;35(8):952-64
pubmed: 26028032
Semin Cell Dev Biol. 2022 Dec;132:146-154
pubmed: 34952788
Oncogene. 2012 Nov 8;31(45):4778-88
pubmed: 22266854
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Cell Int. 2021 Jan 6;21(1):25
pubmed: 33407510
Cancer Lett. 2021 Jun 28;508:115-126
pubmed: 33794309
Clin Epigenetics. 2021 Apr 26;13(1):91
pubmed: 33902700
Cell Death Differ. 2021 Feb;28(2):591-605
pubmed: 33432113
Mol Cancer. 2022 Jul 15;21(1):146
pubmed: 35840930
J Clin Invest. 2020 Dec 1;130(12):6278-6289
pubmed: 32817589
Cell Res. 2016 Apr;26(4):399-422
pubmed: 27012465
Drug Resist Updat. 2020 Jan;48:100663
pubmed: 31785545
Mol Ther. 2021 Jan 6;29(1):291-307
pubmed: 32950106
Cancer Lett. 2019 May 1;449:31-44
pubmed: 30742945
Front Immunol. 2022 Sep 09;13:968755
pubmed: 36159815
Cell Death Differ. 2021 Nov;28(11):3077-3091
pubmed: 34017102
Cell Death Dis. 2018 Apr 19;9(5):456
pubmed: 29674637
Cell Death Differ. 2022 Feb;29(2):439-450
pubmed: 34511601
Nat Commun. 2020 Dec 8;11(1):6298
pubmed: 33293516
J Virol. 2018 Jun 29;92(14):
pubmed: 29743353
J Cell Commun Signal. 2018 Mar;12(1):143-156
pubmed: 29027626
Int J Mol Sci. 2021 Oct 14;22(20):
pubmed: 34681726
Int J Mol Sci. 2021 Sep 28;22(19):
pubmed: 34638806
FASEB J. 2020 Apr;34(4):5754-5766
pubmed: 32103545
Cancer Lett. 2021 May 1;505:13-23
pubmed: 33610730
Int J Biol Sci. 2020 Sep 13;16(15):2924-2937
pubmed: 33061806
Trends Cell Biol. 2017 May;27(5):322-339
pubmed: 28188028
Nat Cell Biol. 2016 May 27;18(6):579-86
pubmed: 27230526
J Cell Biol. 2019 Jun 3;218(6):1776-1786
pubmed: 31000580
Annu Rev Biochem. 1998;67:425-79
pubmed: 9759494
Cancer Commun (Lond). 2022 May;42(5):447-470
pubmed: 35434944
Cancer Res. 2023 May 15;83(10):1666-1683
pubmed: 36939377
Mol Ther. 2019 Feb 6;27(2):326-341
pubmed: 30660488

Auteurs

Kanghua Xiao (K)

Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, Guangdong, PR China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, Guangdong, PR China.

Shengmeng Peng (S)

Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, Guangdong, PR China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, Guangdong, PR China.

Junlin Lu (J)

Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, Guangdong, PR China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, Guangdong, PR China.

Ting Zhou (T)

Biobank of Sun Yat-sen University Cancer Center, Guangzhou, 510120, Guangdong, PR China.

Xuwei Hong (X)

Department of Urology, Shantou Central Hospital, Shantou, 515031, PR China.

Siting Chen (S)

Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, Guangdong, PR China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, Guangdong, PR China.

Guangyao Liu (G)

School of Medicine, South China University of Technology, Guangzhou, 510120, Guangdong, PR China.

Hong Li (H)

BioMed Laboratory, Guangzhou Jingke Biotech Group, Guangzhou, 510120, Guangdong, PR China.

Jian Huang (J)

Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, Guangdong, PR China. huangj8@mail.sysu.edu.cn.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, Guangdong, PR China. huangj8@mail.sysu.edu.cn.
Guangdong Provincial Clinical Research Center for Urological Diseases, Guangzhou, 510120, Guangdong, PR China. huangj8@mail.sysu.edu.cn.

Xu Chen (X)

Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, Guangdong, PR China. chenx457@mail.sysu.edu.cn.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, Guangdong, PR China. chenx457@mail.sysu.edu.cn.
Guangdong Provincial Clinical Research Center for Urological Diseases, Guangzhou, 510120, Guangdong, PR China. chenx457@mail.sysu.edu.cn.

Tianxin Lin (T)

Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, Guangdong, PR China. lintx@mail.sysu.edu.cn.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, Guangdong, PR China. lintx@mail.sysu.edu.cn.
Guangdong Provincial Clinical Research Center for Urological Diseases, Guangzhou, 510120, Guangdong, PR China. lintx@mail.sysu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH